

# Automated and Rapid Microbiological Tests: Market Research Report

<https://marketpublishers.com/r/A6B2F59672BEN.html>

Date: December 2017

Pages: 451

Price: US\$ 5,600.00 (Single User License)

ID: A6B2F59672BEN

## Abstracts

This report analyzes the worldwide markets for Automated and Rapid Microbiological Tests in US\$ Thousand by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.

Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 83 companies including many key and niche players such as -

Abbott Laboratories

Alere Inc.

Beckman Coulter, Inc.

Becton Dickinson and Company

bioMérieux SA



## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

### II. EXECUTIVE SUMMARY

#### 1. INDUSTRY OVERVIEW

Global In-Vitro Diagnostics Market

**Table 1.** Global In-Vitro Diagnostics (IVD) Market by Geographic Region (2015): Percentage Share Breakdown of Revenues for the US, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World (includes corresponding Graph/Chart)

Central Laboratories Dominate the Market

**Table 2.** Global In-Vitro Diagnostics Market by Sector (2015): Percentage Breakdown of Revenues for Hospital & Central Laboratories, Decentralized & Patient Self-Testing (includes corresponding Graph/Chart)

Immunochemistry - the Leading Segment

**Table 3.** Global In-Vitro Diagnostics Market by Segment (2015): Percentage Breakdown of Value Sales for Immunochemistry, Self-Monitoring Blood Glucose, Point-of-Care Diagnostics, Molecular Diagnostics, Tissue Diagnostics, Hematology, Microbiology, and Others (includes corresponding Graph/Chart)

**Table 4.** Global In-Vitro Diagnostics Market by Leading Player (2015): Percentage Share Breakdown of Revenues for Roche, Siemens, Abbott, Danaher, Thermo Fisher Scientific, Becton Dickinson, Alere, Sysmex, bioMerieux, Ortho Clinical Diagnostics, and Others (includes corresponding Graph/Chart)

Automated and Rapid Microbiological Tests Revolutionize Microbiological Testing  
Evolutionary Battle against Microbes Drives Market Future

Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics Market  
Instant Detection of Pathogens – A New Epoch in the Fight for Survival

Traditional Rapid Microbiological Tests Make Way for New, Probe Tests  
Emerging Markets Provide Tremendous Growth Opportunities  
Clinical Applications

**Table 5.** Global Automated and Rapid Microbiological Tests Market in Clinical Applications by Region: (2016) (includes corresponding Graph/Chart)

**Table 6.** Global Automated and Rapid Microbiological Tests Market in Clinical Applications by Segment: (2016) (includes corresponding Graph/Chart)

Non-Clinical Applications

**Table 7.** Global Automated and Rapid Microbiological Tests Market in Non-Clinical Applications by Region: (2016) (includes corresponding Graph/Chart)

A Holistic Peek into a Few Noteworthy Trends

The Evolution of Biotechnology – A Crucial Step Ahead in the Growing Popularity of Rapid Microbial Tests

Point-of-Care Rapid Microbiological Testing: Yet to Realize Its Full Potential...

## 2. COMPETITION

**Table 8.** Global Microorganism Identification and Resistance Tests Market by Leading Player (2015): Percentage Market Share Breakdown of Value Sales for bioMérieux, Becton Dickinson, Thermo Fisher, Beckman Coulter, Others (includes corresponding Graph/Chart)

**Table 9.** Global Blood Screening Market by Leading Player (2015): Percentage Market Share Breakdown of Value Sales for Hologic, Roche and Others (includes corresponding Graph/Chart)

**Table 10.** Global GC-CT Testing Market by Leading Player (2015): Percentage Market Share Breakdown of Value Sales for Hologic, Becton Dickinson, Roche, Qiagen NV, and Others (includes corresponding Graph/Chart)

Competitive Dynamics in the C. Difficile Testing Market

**Table 11.** Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2015): Percentage Breakdown of Revenues for Cepheid, Meridian, Becton Dickinson, and Others (includes corresponding Graph/Chart)

List of Select Molecular C. difficile Test Products

### 3. MARKET DRIVERS AND TRENDS

Increasing Incidence of Infectious Diseases – An Opportunity Indicator  
Rising Healthcare Needs of Aging Global Population – A Growth Driver

**Table 12.** Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)

**Table 13.** Global Population Statistics for 65+ Age Group (2014) (includes corresponding Graph/Chart)

**Table 14.** Aged Population (65+ Years) as a Percentage of the Total Population by Region: 2000 Vis-a-vis 2025 (includes corresponding Graph/Chart)

The World is Ageing

**Table 15.** Elderly Population (65+ Years) as a Percentage of the Total Population: 2014 & 2025 (includes corresponding Graph/Chart)

Rising HIV Prevalence – A Key Opportunity Indicator  
Some Significant HIV Statistics by Region: 2015

**Table 16.** Global Prevalence of HIV Infection in 2015 by Region (in Millions) (includes corresponding Graph/Chart)

**Table 17.** Newly Infected HIV Population in 2015 by Region (in Thousands) (includes corresponding Graph/Chart)

**Table 18.** Global HIV Related Deaths in 2015 by Region (in Thousands) (includes corresponding Graph/Chart)

Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease  
Ultra-Rapid HIV-Screening Tests put up a Strong Fight against HIV-Epidemic  
Accuracy/Reliability of Home HIV Testing: A Bone of Contention  
Increase in Healthcare Spending in Emerging Markets to Propel Demand

**Table 19.** Healthcare Spending as % of GDP by Region (2016E) (includes corresponding Graph/Chart)

**Table 20.** Healthcare Spending as % of GDP in Select Countries (2014) (includes corresponding Graph/Chart)

Rising Emphasis on Lab Automation to Augur Well for Market Growth  
Greater Patient Awareness to Drive Growth  
Advancements in Molecular Diagnostics - A Boon  
Antibiotic Resistant Bacteria Throws the Spotlight on Microbial Testing  
Influenza – Boosting Rapid Test Prospects  
Select FDA-approved Rapid Detection Tests for Flu A&B: (2015)  
Automated Blood Culture Systems: The Gold Standard in the Fight against Bacteremia  
Impact of Food Scares on Rapid Microbiological Tests Market  
Stringent Norms Necessitate Microbial Food Safety Testing  
Rapid Screening Gains Preference over Traditional Food Testing Procedures  
Conventional Testing Continues to Dominate but Rapid Tests Making Inroads  
Leading Food Processors Resort to Rapid Microbiological Testing  
Food Packages of the Future Ingrained with Microbial Alert Systems  
Poultry Industry Embraces Rapid Microbiological Testing Technologies  
Rapid Microbiological Tests Gain Significance in the Pharma Industry  
Key Advantages of Rapid Microbiological Tests for Pharma– In a Nutshell  
Growth Direct System Creates Waves in Pharmaceutical Quality Control

#### **4. KEY ISSUES CONFRONTING THE RAPID MICROBIOLOGICAL TESTS MARKET**

Validation: An Imperative Prerequisite  
Obtaining Regulatory Approval: A Major Non-Technical Hindrance  
Non-Conformance to Testing Requirements: A Weighty Concern  
Technical and Cost Issues Impede the Uptake of Rapid Microbiological Tests in the

Food Sector

## **5. PRODUCT/TECHNOLOGY OVERVIEW**

## **6. APPLICATION AREAS OF AUTOMATED AND RAPID MICROBIOLOGICAL TESTS – A REVIEW**

Clinical Applications

Automated Identification and Susceptibility Systems

Automated Blood Culture Systems

Automated Tuberculosis Systems

Streptococcus Infection Rapid Tests

GC/Chlamydia Rapid Tests

Other Automated & Rapid Microbiological Tests

Applications in Non-Clinical Investigations

Food/Water Safety Tests

Rapid Microbiological Methods in Pharmaceutical Sector

Environmental Tests

Other Miscellaneous Applications

## **7. PRODUCT INNOVATIONS/INTRODUCTIONS**

bioMerieux Launches New Platform for Extraction of DNA and RNA

Bio-Rad Launches IH-1000 Blood Typing System

bioMerieux Launches 'EviSight Compact' Incubator System

BD Launches Next Generation Automated ID/AST System

Sekisui Introduces SEKURE TPLA and RPR Assays for Syphilis Testing

BD Introduces BD Veritor Plus System

Rhoenix Introduces Beer SpoilerAlert Assay

Philips Introduces Minicare I-20 System

Bio-Rad Introduces Amplichek II Quality Control

Bruker Launches Enhancements for MALDI Biotyper

Thermo Fisher Launches Thermo Scientific SureTect Cronobacter Species Real-Time PCR Assay

Hologic Introduces Aptima Mycoplasma Genitalium Assay

bioMerieux and Illumina Introduce bioMerieux EpiSeq

bioMerieux Launches GENE-UP

BioControl Launches Modular Automation for Assurance GDS

Rapid Micro Biosystems Launches Growth Direct System

IDEXX Launches Quanti-Tray Sealer PLUS in Europe  
Sekisui Introduces 3 New Assays to the OSOM Rapid Test Line  
Bio-Rad Launches IH-500  
bioMerieux Launches VIDAS Lyme IgG II and VIDAS Lyme IgM II Assays in the US  
Meridian Introduces illumigene HSV Assays in Europe  
Medicinal Genomics Introduces PathogINDICATOR Assay  
Roche Introduces cobas DPX Test

## **8. RECENT INDUSTRY ACTIVITY**

Abbott Files for Cancellation of Acquisition Agreement with Alere  
Hologic Obtains CE Mark Approval for Aptima HSV Assay  
Hologic Obtains Health Canada Approval for Aptima Hepatitis C and B Quant Assays  
Quidel Obtains FDA Approval for Solana Assay for Various Streptococcus Strains  
Quidel Obtains FDA Approval for Solana Assay for Influenza A&B  
BD Receives FDA Approval for BD MAX CT/GC/TV Assay  
OraSure Obtains BARDA Funding for Zika Tests  
Alere Obtains FDA Approval for Alere i RSV Rapid Molecular Test  
Magellan Diagnostics Obtains Chinese Approval for LeadCare II  
Alere Receives CE Mark for Alere Reader  
Sekisui Secures Distribution Rights for FastPack IP System from Qualigen  
bioMerieux Submits 510(k) Application for BacT/ALERT VIRTUO  
Alere Begins Operations at New Facility in India  
Alere Obtains WHO Prequalification for Alere HIV Combo  
Hologic and Grifols Receive FDA Approval for Procleix Zika Virus Assay  
Meridian Obtains FDA Approval for illumigene Mycoplasma Direct Assay  
Alere Announces WHO Prequalification for Alere q HIV-1/2 Detect Assay  
BD and Check-Points Enter into Development and Distribution Agreement  
Luminex to Acquire Nanosphere  
bioMerieux Takes Over Hyglos  
BD Receives CE Mark for BD MAX Vaginal Panel  
Siemens Healthcare Changes Name to Siemens Healthineers  
Sekisui and Qualigen Enter into Partnership  
Meridian Obtains CE Mark for illumigene Mycoplasma Direct  
BioFire Obtains FDA and CE Mark Approval for FilmArray Torch use with all FilmArray Panels  
Roche Receives FDA IND Approval for cobas Zika Assay  
Meridian Takes Over Magellan Biosciences  
Thermo Fisher Obtains FDA Approval for B•R•A•H•M•S PCT Assay for Sepsis Risk



## Assessment

BioFire Obtains FDA Approval for FilmArray Torch for use with FilmArray Respiratory Panel

Abbott Signs Acquisition Agreement with Alere

Siemens Receives FDA Approval for Sysmex CS-2100i System

Bio-Rad Receives FDA Approval for TANGO infinity system

Bio-Rad Obtains FDA Approval for D-100 System for A1c Testing

MedMira Obtains FDA Approval for Reveal G4 Rapid HIV-1 Antibody Test

FDA Approves cobas HBV and cobas HCV Viral Load Tests for cobas 6800 and cobas 8800 Systems

Hologic Obtains CE-IVD Certification for Aptima HCV Quant Dx Assay on Panther System

BD and Seegene Enter into Collaboration Agreement

FDA Emergency Authorization for OraSure OraQuick Ebola Rapid Antigen Test

Bio-Rad Obtains Pre-Market Approval for BioPlex 2200 HIV Ag-Ab Assay

FDA Approves VIDAS 3 Immunoassay from bioMerieux

Meridian Obtains FDA Approval for illumigene HSV 1&2

Charles River Laboratories Acquires Celsis International

FDA Approves Quidel Solana Molecular System and Solana Molecular Assay

FDA Approves Roche cobas HSV 1 and 2 Test

FDA Approves Roche cobas Cdiff Test

MedMira Submits Supplement for FDA Approval of Reveal G4 Rapid HIV-1 Antibody Test

FDA Approves Alere i Strep A Rapid Molecular Test

bioMerieux Acquires CREERAM Tools

FDA Gives CLIA Waiver Alere i Influenza A & B Test

Alere Obtains CE Mark Approval for Alere HIV Combo

Alere Obtains IVD CE Mark Approval for Alere q HIV-1/2 Detect Assay for Molecular Diagnosis of HIV at the Point of Care

FDA Gives CLIA Waiver for Alere i Strep A Rapid Molecular Test

BioFire Obtains FDA Approval and CE-IVD Marking for FilmArray 2.0 System

FDA Approves Next Generation cobas MRSA/SA Test of Roche

FDA Approves cobas TaqScreen MPX Test, v2.0 of Roche

bioMerieux Signs Strategic Agreement with COPAN

## 9. FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (US)

Abbott Molecular, Inc. (US)

Alere Inc. (US)  
Beckman Coulter, Inc. (US)  
Becton Dickinson and Company (US)  
bioMerieux SA (France)  
bioMerieux, Inc. (US)  
Bio-Rad Laboratories, Inc (US)  
Cellabs Pty Ltd (Australia)  
Cepheid Inc. (US)  
CorisBioconcept SPRL (Belgium)  
F. Hoffmann-La Roche AG (Switzerland)  
Hologic, Inc. (US)  
MedMira Inc. (Canada)  
Meridian Bioscience, Inc. (US)  
OraSure Technologies, Inc. (US)  
Orion Diagnostica Oy (Finland)  
QIAGEN N. V. (The Netherlands)  
Quidel Corporation (US)  
Sekisui Diagnostics, LLC (US)  
Siemens Healthcare GmbH (Germany)  
Thermo Fisher Scientific Inc. (US)  
Oxoid Limited (UK)

## 10. GLOBAL MARKET PERSPECTIVE

**Table 21.** World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 22.** World Historic Review for Automated and Rapid Microbiological Tests by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 23.** World 14-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for

Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 24.** World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 25.** World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 26.** World 14-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 27.** World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 28.** World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 29.** World 14-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Percentage Breakdown of Dollar Sales for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Markets for Years

2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 30.** World Recent Past, Current & Future Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 31.** World Historic Review for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 32.** World 14-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 33.** World Recent Past, Current & Future Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 34.** World Historic Review for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 35.** World 14-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 36.** World Recent Past, Current & Future Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 37.** World Historic Review for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 38.** World 14-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 39.** World Recent Past, Current & Future Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 40.** World Historic Review for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 41.** World 14-Year Perspective for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 42.** World Recent Past, Current & Future Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 43.** World Historic Review for GC/Chlamydia Rapid Tests in Clinical Applications



by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 44.** World 14-Year Perspective for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 45.** World Recent Past, Current & Future Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 46.** World Historic Review for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 47.** World 14-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 48.** World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 49.** World Historic Review for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 50.** World 14-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

### III. MARKET

#### 1. THE UNITED STATES

A. Market Analysis  
Current & Future Analysis

**Table 51.** Healthcare Spending as a % of GDP (includes corresponding Graph/Chart)

Positive Outlook for Rapid and Automated Microbiological Tests Market  
Rapidly Ageing Demographics Drive Growth

**Table 52.** North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)

Competition  
Tracking Trends Across Product Segments  
Automated Identification & Susceptibility Systems  
Growing Popularity of FDA-Approved Automated Susceptibility Testing Equipment  
STD Rapid Tests  
Market Shares of Leading Players

**Table 53.** The US Market for Syphilis Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Becton Dickinson, Alere, and Others (includes corresponding Graph/Chart)

Gastrointestinal Rapid Tests

**Table 54.** The US Market for Rotavirus Rapid Tests by Leading Player (2015) -

Percentage Breakdown of Value Sales for Meridian Biosciences, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)

Respiratory Rapid Tests

Competition

Market Share Data of Leading Players

**Table 55.** The US Market for Influenza Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Quidel, Becton Dickinson, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)

**Table 56.** The US Market for RSV Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Becton Dickinson, Binax, Thermo Fisher Scientific and Others (includes corresponding Graph/Chart)

**Table 57.** The US Market for Mononucleosis Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Alere, Oxoid, Quidel and Others (includes corresponding Graph/Chart)

Streptococcus Infection Rapid Tests

**Table 58.** The US Market for Streptococcus A Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Quidel, Thermo Fisher Scientific, Becton Dickinson, and Others (includes corresponding Graph/Chart)

Testing Practices of the US Food Industry

**Table 59.** US Food Safety Testing Market by Contaminant (2015): Percentage Breakdown of Value Sales for Pathogens, GMOs, Toxins, Residues and Others (includes corresponding Graph/Chart)

Increasing Demand for Microbiology Tests in the Food Sector

**Table 60.** US Microbiological Food Safety Tests by Type (2015): Percentage Share Breakdown in terms of Number of Tests for Routine Tests and Pathogen Tests



(includes corresponding Graph/Chart)

## Tackling the Burden of Food Borne Illnesses

**Table 61.** Food-borne Illnesses, Hospitalizations and Deaths in the US (2011): Percentage Share Breakdown for Known Pathogens and Unspecified Agents (includes corresponding Graph/Chart)

**Table 62.** Leading Known Pathogens Causing Food-borne Illnesses in the US (2011): Percentage Share Breakdown of Number of Illnesses by Known Pathogens - Norovirus, Salmonella nontyphoidal, Clostridium perfringens, Campylobacter spp., Staphylococcus aureus, and Others (includes corresponding Graph/Chart)

**Table 63.** Leading Known Food-borne Pathogens Causing Hospitalizations in the US (2011): Percentage Share Breakdown of Number of Hospitalizations by Known Pathogens - Salmonella nontyphoidal, Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli (STEC) O157, and Others (includes corresponding Graph/Chart)

**Table 64.** Leading Known Food-borne Pathogens Causing Deaths in the US (2011): Percentage Share Breakdown of Number of Deaths by Known Pathogens - Salmonella nontyphoidal, Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli (STEC) O157, and Others (includes corresponding Graph/Chart)

## Product Launches

## Strategic Corporate Developments

## Select Key Players

## B. Market Analytics

**Table 65.** The US Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 66.** The US Historic Review for Automated & Rapid Microbiological Tests by End-

Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 67.** The US 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 2. CANADA

### A. Market Analysis

#### Current & Future Analysis

#### Food Safety Testing in Canada

**Table 68.** Canadian Food-Borne Illnesses by Category (2012): Percentage Share Breakdown of Number of Illness Caused through Known Pathogens and Unknown Pathogens (includes corresponding Graph/Chart)

**Table 69.** Canadian Food-Borne Illnesses by Pathogen (2012): Percentage Breakdown of number of Illness Caused by Norovirus, Clostridium perfringens, Campylobacter spp, Salmonella spp., non-typhoidal and Others (includes corresponding Graph/Chart)

### Strategic Corporate Development

#### Medmira Inc. – A Key Player

### B. Market Analytics

**Table 70.** Canadian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical

Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 71.** Canadian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 72.** Canadian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

### 3. JAPAN

#### A. Market Analysis

##### Current & Future Analysis

##### Demographics Drive Market Growth

**Table 73.** Japanese Population by Age Group (2012) (includes corresponding Graph/Chart)

**Table 74.** Japanese 65+ Years Population Share of Total Population: 1950-2015 (includes corresponding Graph/Chart)

#### B. Market Analytics

**Table 75.** Japanese Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical

Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 76.** Japanese Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 77.** Japanese 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 4. EUROPE

### A. Market Analysis

#### Current & Future Analysis

#### Debt Crisis in Europe Affects Healthcare Industry

#### European Healthcare System: In a State of Transition

#### Ageing Demography – An Opportunity Indicator

**Table 78.** Population Breakup by Age Group for Select European Countries: 2015 (as Percentage of Total Population) (includes corresponding Graph/Chart)

#### Clinical Vis-a-vis Non-clinical Applications

#### What Drives the Requirement Patterns of End-Users?

#### Proliferation of Automated, and Rapid Tests in Clinical Applications

#### Non-Clinical Applications

**Table 79.** European Microbiological Food Safety Tests (2015): Percentage Share Breakdown of Number of Tests by Segment - Routine Tests and Pathogen Tests (includes corresponding Graph/Chart)

Strategic Corporate Developments

Product Launches

B. Market Analytics

**Table 80.** European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 81.** European Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014(includes corresponding Graph/Chart)

**Table 82.** European 14-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 83.** European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 84.** European Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 85.** European 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood

Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **4A. FRANCE**

##### **A. Market Analysis**

Current & Future Analysis

Product Launches

Strategic Corporate Developments

bioMerieux SA - A Key Player

##### **B. Market Analytics**

**Table 86.** French Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 87.** French Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 88.** French 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **4B. GERMANY**



#### A. Market Analysis

##### Current & Future Analysis

Food Safety – A Cause of Concern

Food Safety Regulations in Germany

Strategic Corporate Developments

Siemens Healthcare GmbH – A Key Player

#### B. Market Analytics

**Table 89.** German Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 90.** German Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 91.** German 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 4C. ITALY

#### A. Market Analysis

##### Current & Future Analysis

#### B. Market Analytics

**Table 92.** Italian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 93.** Italian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 94.** Italian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **4D. THE UNITED KINGDOM**

##### **A. Market Analysis**

##### **Current & Future Analysis**

##### **Non-Clinical Applications to Exhibit Fastest Growth**

##### **Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics**

##### **Oxoid Limited – A Key Player**

##### **B. Market Analytics**

**Table 95.** The UK Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical



Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 96.** The UK Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 97.** The UK 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **4E. SPAIN**

A. Market Analysis

Current & Future Analysis

B. Market Analytics

**Table 98.** Spanish Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 99.** Spanish Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes

corresponding Graph/Chart)

**Table 100.** Spanish 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **4F. RUSSIA**

A. Market Analysis

Current & Future Analysis

B. Market Analytics

**Table 101.** Russian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 102.** Russian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 103.** Russian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes

corresponding Graph/Chart)

#### **4G. REST OF EUROPE**

A. Market Analysis

Current & Future Analysis

Product Launches

Key Players

B. Market Analytics

**Table 104.** Rest of Europe Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 105.** Rest of Europe Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 106.** Rest of Europe 14-Year Perspective for Automated & Rapid Microbiological Tests by End-use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **5. ASIA-PACIFIC**

A. Market Analysis

Current & Future Analysis

## Healthcare Spending in Asia-Pacific on the Rise India & China Offer Significant Growth Opportunities

**Table 107.** China and India Lead Global Population (2013): Table Depicting China and India's Huge Population Vis-a-vis Other Countries' Population (in Million) by Age Group (includes corresponding Graph/Chart)

**Table 108.** Age-wise Breakup of China and India's Population Vis-a-vis Other Populous Countries Globally (2013) (includes corresponding Graph/Chart)

## Asia-Pacific – The Next Epicenter for the AIDS Epidemic B. Market Analytics

**Table 109.** Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 110.** Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 111.** Asia-Pacific 14-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 112.** Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 113.** Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by

End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 114.** Asia-Pacific 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 5A. CHINA

### A. Market Analysis

#### IVD Market - An Overview

**Table 115.** Leading Players in the Chinese In-Vitro Diagnostics Market (2012): Percentage Breakdown of Value Sales for Abbott, Beckman/ Danaher, BioMerieux, DA AN, Hitachi, J&J, Mindray, Roche, Siemens, Sysmex and Others (includes corresponding Graph/Chart)

### Current & Future Analysis

#### Strategic Corporate Development

### B. Market Analytics

**Table 116.** Chinese Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 117.** Chinese Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 118.** Chinese 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 5B. INDIA

### A. Market Analysis

#### Current & Future Analysis

Demand for Automated and Rapid Microbiology Testing Set to Grow in India

#### Growth Drivers

Automation – Name of the Game

Strategic Corporate Development

### B. Market Analytics

**Table 119.** Indian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 120.** Indian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated



& Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 121.** Indian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 5C. REST OF ASIA-PACIFIC

### A. Market Analysis

#### Current & Future Analysis

#### Strategic Corporate Development

#### Cellabs Pty Ltd (Australia) – A Key Australian Player

### B. Market Analytics

**Table 122.** Rest of Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 123.** Rest of Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 124.** Rest of Asia-Pacific 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated

Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## **6. LATIN AMERICA**

### **A. Market Analysis**

#### **Current & Future Analysis**

### **B. Market Analytics**

**Table 125.** Latin American Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 126.** Latin American Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 127.** Latin American 14-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 128.** Latin American Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 129.** Latin American Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated



& Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 130.** Latin American 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 6A. BRAZIL

A. Market Analysis

Current & Future Analysis

B. Market Analytics

**Table 131.** Brazilian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 132.** Brazilian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 133.** Brazilian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid

Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## **6B. REST OF LATIN AMERICA**

A. Market Analysis

Current & Future Analysis

B. Market Analytics

**Table 134.** Rest of Latin America Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 135.** Rest of Latin America Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 136.** Rest of Latin America 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## **7. REST OF WORLD**

A. Market Analysis

Current & Future Analysis

## B. Market Analytics

**Table 137.** Rest of World Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 138.** Rest of World Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 139.** Rest of World 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 83 (including Divisions/Subsidiaries -90)

The United States (55)

Canada (1)

Japan (4)

Europe (27)

France (3)

Germany (9)

The United Kingdom (3)

Italy (2)

Spain (1)

Rest of Europe (9)  
Asia-Pacific (Excluding Japan) (2)  
Middle East (1)

## I would like to order

Product name: Automated and Rapid Microbiological Tests: Market Research Report

Product link: <https://marketpublishers.com/r/A6B2F59672BEN.html>

Price: US\$ 5,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A6B2F59672BEN.html>